These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia. Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131 [TBL] [Abstract][Full Text] [Related]
4. Increased urinary coproporphyrin excretion observed in patients with differently staged Hodgkin's disease treated with chemotherapy. Pinelli A; Mussini C; Buratti M; Parmiggiani-Venezia M; Trivulzio S Pharmacol Res; 2005 Mar; 51(3):283-8. PubMed ID: 15661580 [TBL] [Abstract][Full Text] [Related]
5. The anemias, with particular reference to classification and to alterations in the erythrocyte protoporphyrin and urinary coproporphyrin. WATSON CJ Bol Asoc Med P R; 1948 Feb; 40(2):43-7. PubMed ID: 18916044 [No Abstract] [Full Text] [Related]
7. Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases. Demirçay Z; Gürbüz O; Alpdoğan TB; Yücelten D; Alpdoğan O; Kurtkaya O; Bayik M Int J Dermatol; 1997 Aug; 36(8):593-8. PubMed ID: 9329890 [TBL] [Abstract][Full Text] [Related]
8. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia. Usui N; Dobashi N; Kobayashi T; Yano S; Maki N; Asai O; Saito T; Yamaguchi Y; Watanabe H; Kato A; Ogihara A; Katori M; Nagamine M; Takei Y; Yamazaki H; Funakoshi S; Tajima N; Ogawa M; Kuraishi Y J Clin Oncol; 1998 Jun; 16(6):2086-92. PubMed ID: 9626208 [TBL] [Abstract][Full Text] [Related]
9. High-dose versus standard-dose daunorubicin in induction therapy for young patients with de novo acute myeloid leukaemia: a meta-analysis of randomised trials. Su L; Zhu X; Gao S; Li W; Liu X; Tan Y J Chemother; 2016 Apr; 28(2):123-8. PubMed ID: 27104964 [TBL] [Abstract][Full Text] [Related]
10. Generalized hyperpigmentation with daunorubicin chemotherapy. Kroumpouzos G; Travers R; Allan A J Am Acad Dermatol; 2002 Feb; 46(2 Suppl Case Reports):S1-3. PubMed ID: 11807454 [TBL] [Abstract][Full Text] [Related]
11. Daunorubicin-induced hyperpigmentation. Pol RR; Wright A; Hill A Br J Haematol; 2010 Dec; 151(5):414. PubMed ID: 21029070 [No Abstract] [Full Text] [Related]
12. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004 [TBL] [Abstract][Full Text] [Related]
13. Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. Devillier R; Bertoli S; Prébet T; Huguet F; Etienne A; Charbonnier A; Rey J; Delabesse E; D'Incan E; Huynh A; Blaise D; Récher C; Vey N Am J Hematol; 2015 Feb; 90(2):E29-30. PubMed ID: 25363834 [No Abstract] [Full Text] [Related]
14. [Rubidomycin in the treatment of leukemias in children (preliminary clinical observation)]. Zinkiewicz Z; Wróblewska B Wiad Lek; 1969 Jan; 22(2):155-8. PubMed ID: 5252540 [No Abstract] [Full Text] [Related]
15. Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia. Skorokhod OA; Garmaeva TTs; Vitvitsky VM; Isaev VG; Parovichnikova EN; Savchenko VG; Ataullakhanov FI Med Sci Monit; 2004 Apr; 10(4):PI55-64. PubMed ID: 15039656 [TBL] [Abstract][Full Text] [Related]
16. Daunorubicin 90 mg/m Portugal R; Lyrio R; Loureiro M; Urago K; Bard J; Borchardt A; Garnica M; Nucci M Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):527-531. PubMed ID: 28842139 [TBL] [Abstract][Full Text] [Related]